Cameron is completing a PhD in the Howarth Lab at the University of Cambridge, UK. His research focuses on engineering highly stable antibody mimetic proteins for action in the gastrointestinal tract. Disease targets of particular interest include the inflammatory pathways involved in IBD, the microbiome, food intolerances and microbial infection. Cameron completed a masters degree in the Biggin Group (University of Oxford) using protein MD simulation and high-throughput fragment-based drug design to inhibit novel cancer targets. He now uses this computational experience to complement protein display technologies for antibody design. Cameron is also involved in growing the new chapter of Nucleate in the UK.

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

I’d love to see some causative rather than correlative data for the influence of the microbiome of human health and disease. I have personal reasons to want the development of a cure for Parkinson’s disease. I think the extension of healthy lifespan by targeting aging itself is an interesting all-in-one concept for healthcare. Perhaps in my lifetime we will see the discovery of the elusive partial epigenetic reprogramming factors that can rejuvenate specialized cell types.

WHAT EXCITES YOU ABOUT ARTIS

For starters, it is always exciting for a Brit to venture over to The Valley! Joking aside, I am impressed by the clarity of vision at ARTIS. Using the consistency of tech innovation to give life science ideas the boost they often require is really exciting - and ARTIS has the team to do it. I think it’s all about people - the partners, the network of advisors, the amazing founders and the other fellows - that is the secret sauce. I’m excited to learn from these remarkable people and contribute to the ARTIS family.

‍

RECENT INNOVATION OR DISCOVERY THAT HAS HAD GREATEST IMPACT ON TECH/HEALTH

Having one foot in computational protein design, it would be remiss not to mention AlphaFold. While I think we’ll be waiting a fair while before ML is spitting out de novo, high affinity biologics without requiring some additional wet-lab development, AlphaFold has really opened up the game.